Acyclovir
- Generic Name
- Acyclovir
- Brand Names
- Sitavig, Xerese, Zovirax
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N5O3
- CAS Number
- 59277-89-3
- Unique Ingredient Identifier
- X4HES1O11F
- Background
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Acyclovir was granted FDA approval on 29 March 1982.
- Indication
An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutan...
- Associated Conditions
- Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
- Associated Therapies
- -
Acyclovir in Mechanically Ventilated Patients With Pneumonia and HSV-1 in BAL
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 710
- Registration Number
- NCT06134492
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany
🇩🇪Universitätsklinikum Augsburg, Augsburg, Bayern, Germany
🇩🇪RoMed Klinikum Rosenheim, Rosenheim, Bayern, Germany
Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 20
- Registration Number
- NCT05589688
- Locations
- 🇫🇷
Toulouse Hospital, Toulouse, France
Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 44
- Registration Number
- NCT05324904
- Locations
- 🇪🇬
Assuit University, Assiut, Egypt
Effect of Various Treatment Modalities on Dendritic Vial Ulcer
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 40
- Registration Number
- NCT05313828
- Locations
- 🇪🇬
Sohag University, Sohag, Egypt
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Dalia Mahran
- Target Recruit Count
- 35
- Registration Number
- NCT04476186
- Locations
- 🇪🇬
Hamdy Gomaa, Assiut, New Assiut City, Egypt
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 104
- Registration Number
- NCT04132115
- Locations
- 🇮🇹
Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy
🇮🇹Terapia Intensiva 1, Udine, Italy
Melatonin Effects on Genital Herpes in Brazilian Women
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03831165
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
🇧🇷Avenida Doutor Eneas Carvalho de Aguiar 255 10 andar, São Paulo, SP, Brazil
A Clinical Trial of Acyclovir for Viral Uveitis
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Xiaomin Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT03389191
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 16
- Registration Number
- NCT03368664
- Locations
- 🇹🇷
Investigational Site Number :7920002, Ankara, Turkey
🇹🇷Investigational Site Number :7920001, Ankara, Turkey
🇫🇷Investigational Site Number :2500002, Strasbourg, France
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT03178149
- Locations
- 🇺🇸
Retina Specialty Institute, Pensacola, Florida, United States
🇺🇸Emory University Eye Center, Atlanta, Georgia, United States
🇺🇸Retina Consultants of Southwest Florida & National Ophthalmic Research Institute, Fort Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.